Détention brevets de la classe A61K 31/137

Brevets de cette classe: 4690

Historique des publications depuis 10 ans

399
375
371
401
404
429
411
373
350
267
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Propriétaires principaux

Proprétaire
Total
Cette classe
Antecip Bioventures II LLC
346
196
Novartis AG
10626
54
The Regents of the University of California
20268
51
Grünenthal GmbH
558
42
Zogenix International Limited
76
42
Nalpropion Pharmaceuticals LLC
70
39
The Procter & Gamble Company
21999
38
Axsome Therapeutics, Inc.
280
33
Nevakar Injectables Inc.
45
31
Gruenenthal GmbH
108
28
Noven Pharmaceuticals, Inc.
90
27
Aquestive Therapeutics, Inc.
181
26
Radius Pharmaceuticals, Inc.
52
23
The Trustees of Columbia University in the City of New York
3599
22
Pharnext
87
22
Duke University
3106
20
Institut National de La Sante et de La Recherche Medicale (inserm)
2967
20
The United States of America, as represented by the Secretary, Department of Health and Human Services
2903
20
Ironshore Pharmaceuticals & Development, Inc.
36
19
Clexio Biosciences Ltd.
104
18
Autres propriétaires 3919